Epalrestat
SIGMA/SML0527 - ≥98% (HPLC)
Synonym: (5Z)
CAS Number: 82159-09-9
Empirical Formula (Hill Notation): C15H13NO3S2
Molecular Weight: 319.40
Linear Formula: C15H13NO3S2
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | yellow to orange |
| form | powder |
| InChI | 1S/C15H13NO3S2/c1-10(7-11 |
| InChI key | CHNUOJQWGUIOLD-NFZZJPOKSA |
| Quality Level | 100 ![]() |
| SMILES string | S1C(=C/C(=C/c2ccccc2)/C) |
| solubility | DMSO: 5 mg/mL, clear (warmed) |
| storage condition | protect from light |
| storage temp. | −20°C |
| Application: | Epalrestat has been used as an aldose reductase inhibitor: • in the dahomey larvae diet fed forDrosophila • for non-irradiated and X-ray irradiated human aldose reductase • to test its protective effect in mice with bleomycin-induced pulmonary fibrosis |
| Biochem/physiol Actions: | Epalrestat inhibits Aldose Reductase (AR) involved in the rate limiting step in the conversion of glucose to sorbitol under hyperglycemic conditions. Aldose reductase has been the target of multiple clinical investigatons to treat diabetic neuropathy and retinopathy. Epalrestat is an approved drug in Japan and India, used for the treatment of diabetic neuropathy. |
| Biochem/physiol Actions: | Epalrestat is an Aldose Reductase inhibitor. |
| Features and Benefits: | This compound is featured on the Dopamine and Norepinephrine Metabolism page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here . |
| Other Notes: | Light sensitve |
| Packaging: | 10, 50 mg in glass bottle |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | −20°C |
| UNSPSC | 12352200 |

